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ABSTRACT 28 
Objective: Cancer initiation and progression has been linked to aberrant expression of the DNA 29 
methyltransferases (DNMT), the enzymes which establish and maintain DNA methylation patterns 30 
throughout the genome. In this study, we investigated if DNMT expression in vulvar squamous cell 31 
carcinomas (VSCC) was related to clinical outcome.  32 
 33 
Methods: DNMT1, DNMT3A and DNMT3B expression was measured in a subset of cases drawn 34 
from a cohort of consecutive women treated for primary VSCC at the Pan Birmingham 35 
Gynaecological Cancer Centre between 2001 and 2008. Univariable and multivariable competing risk 36 
modelling was performed to identify whether DNMT expression was associated with local disease 37 
recurrence or disease morbidity.  38 
 39 
Results: Over-expression of DNMT3A in the invasive component of the tumour was seen in 44% of 40 
tumours and was associated with an increased risk of local vulval recurrence (LVR) (HR = 4.51, p = 41 
0.012). This risk was found to increase further after adjustment for disease stage (HR = 6.00, p = 42 
0.003) and groin node metastasis (HR = 4.81, p = 0.008). Over-expression of DNMT3B was 43 
associated with an increased risk of LVR (HR = 5.69 p = 0.03), however this ceased to be significant 44 
after adjustment for groin node metastasis. In a subset analysis, over-expression of DNMT3A was 45 
found to be significantly more common in VSCCs that stained negative for CDKN2A. 46 
 47 
Conclusions: These observations are consistent with the possibility that epigenetic changes contribute 48 
to vulval neoplasia and DNMT3A over-expression may be useful in predicting local disease 49 
recurrence. 50 
 51 
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Introduction 52 
Vulvar squamous cell carcinoma (VSCC) is relatively rare, accounting for approximately 5% of all 53 
gynecological malignancies and 95% of all vulvar malignancies [1]. However the incidence of VSCC 54 
has recently been rising, leading to increased clinical and scientific interest to improve therapeutic 55 
options [2-4]. Over the last two decades evidence has accumulated to show there are two different 56 
aetio-pathogenic pathways of the precursor lesions, termed vulvar intra-epithelial neoplasia (VIN) [5]. 57 
The first, usual type vulvar intraepithelial neoplasia (uVIN) is related to human papillomavirus (HPV) 58 
infection, predominantly type 16. The second pathway which is independent of HPV infection is 59 
referred to as differentiated VIN (dVIN) [6], and is often associated with Lichen Sclerosis (LS), a 60 
non-neoplastic, chronic inflammatory dermatosis with distinctive histology [7,8].  Although there is 61 
evidence to suggest that HPV-derived tumours confer a better survival over their HPV-independent 62 
counterpart in squamous cell cancer of the head and neck, such an advantage in survival is yet to be 63 
established in VSCC [9]. The rate of local vulval recurrence (LVR) has not changed over the last 3 64 
decades and remained at around 25% despite the introduction of chemo-radiotherapy as an adjunct to 65 
surgery [10-12]. Our recent cohort study suggests that women with VSCC arising in the background 66 
of LS were more likely to develop LVR even when the primary tumours were completely excised 67 
with adequate excision margins [13].  68 
 69 
DNA methylation is a covalent modification of DNA tightly regulated by a group of three enzymes 70 
known as the DNA methyltransferases (DNMT). In normal cells DNMT1 is primarily responsible for 71 
maintaining methylation; however its importance in maintaining cancer stem cells and driving 72 
tumorigenesis is also well established [14-16]. DNTM3A and DNMT3B are active de novo 73 
methyltransferases, although expressed at lower levels in adult somatic cells, they have been shown to 74 
be overexpressed and associated with adverse prognosis in several tumours including those of 75 
epithelial origin [17-19]. A recent study has shown that tumour suppressor gene (TSG) methylation in 76 
VSCC is associated with a poor disease prognosis however whether DNMT expression could be 77 
useful in determining disease prognosis remains unclear [20].  78 
 79 
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In this study, we compare for the first time, the expression of DNMT1, DNMT3A and DNMT3B in 80 
the invasive component and in the normal adjacent epithelium of 66, 66 and 62 VSCC cases 81 
respectively, and associated their expression with clinical data collected from patient’s medical 82 
records and CDKN2A status. 83 
 84 
Materials and methods 85 
Vulval tumour study population:  86 
DNMT expression was examined in a subset of cases drawn from a cohort of 201 consecutive patients 87 
first diagnosed with VSCC between 2000 and 2008. All patients were actively followed up for at least 88 
5 years with cause of death assigned using information from multiple sources which included hospital 89 
and hospice notes, general practitioner summaries, cancer registry records and information supplied 90 
by the patient’s family. Information on the following variables from case notes was documented: age, 91 
smoking behaviour, multifocal disease, tumour differentiation, lymphovascular space involvement, 92 
stage, groin node involvement and the presence of concomitant non-neoplastic epithelial disorders. 93 
Information on local, regional and distant recurrences was also recorded during the follow-up period. 94 
Tissue was obtained with written consent and the use of the biopsy material for research purposes had 95 
been approved by the Birmingham, East, North and Solihull Research Ethics Committee (Reference 96 
number 11/WM/0070). 97 
 98 
Preparation of study material:  99 
Paraffin embedded blocks were sectioned every 4µm and one section stained with haematoxylin and 100 
eosin; sequential sections were used for routine immunohistochemical staining with the last of these 101 
sections used for HPV DNA testing as described previously [13]. To avoid cross contamination, the 102 
microtome blades were changed between cutting of each block. Tumour enriched tissue was macro 103 
dissected and DNA was extracted using AllPrep DNA/RNA FFPE (formalin fixed paraffin 104 
embedded) kit, according to manufacturer’s instructions (Qiagen) and stored at -20oC. 105 
 106 
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Immunohistochemical analysis: 107 
DNMT immunohistochemistry  108 
Immunohistochemistry to examine the expression of DNMT1, DNMT3A and DNMT3B was 109 
performed on 66, 66 and 62 VSCC cases respectively. We included only those cases which had 110 
tumour and adjacent normal epithelium, and which performed similarly in two independent 111 
experiments to control for batch variation; thus accounting for the number of cases used in this study. 112 
Antigen expression was assessed using methods we have previously described [21].  Primary 113 
antibodies to DNMT1 (ab19905 – ABCAM), DNMT3A (HPA026588-SIGMA) and DNMT3B 114 
(HPA001595-SIGMA) were used at optimal working dilutions of 1:1200, 1:200, and 1:800 115 
respectively. FFPE tissues from tonsil and skin were used as controls.  116 
Two pathologists (RG, MP), independently reviewed the IHC stained slides. Distinctive brown DAB 117 
nuclear staining was considered as positive for DNMT1, DNMT3A and DNMT3B protein expression. 118 
All invasive vulvar cancer tissue sections were initially scanned at x4 objective to select the most 119 
tumour dense area. Then one field at x10 objective was selected and the total number of DNMT 120 
expressing tumour cells was assessed. When assessing keratinising sub-types of VSCC, it was noted 121 
that the lack of nuclei in the keratin layer result in an apparent lack of staining. In such instances, 122 
staining of nucleated layers was assessed. 123 
CDKN2A immunohistochemistry  124 
43 tumours which were stained for DNMT expression were also tested for CDKN2A expression. A 125 
primary antibody to CDKN2A (clone E6H4 – CINtec) was used at an optimal working dilution of 126 
1:25. Expression was considered positive when there was diffuse block staining of a segment of 127 
epithelium. Patchy staining, even of strong intensity, or staining of varied intensity was considered 128 
negative [22].  129 
H scoring  130 
The H-score scoring system was used to quantify the immunohistochemical staining. The score is 131 
based on the proportion of target nuclei stained and the intensity of the stain [23]. The formula used 132 
is: 3 x percentage of strongly stained nuclei (colour = brownish black) + 2 x percentage of moderately 133 
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stained nuclei (colour = brown) + 1 x percentage of weakly stained nuclei (colour = light brown) + 0 x 134 
percentage of absent staining nuclei. Thus the H-score generated a range from 0 to 300, where 300 is 135 
equivalent to 100% of the cells of interest exhibiting strong staining. DNMT were considered over-136 
expressed when the H score of the tumour was greater than that of the normal adjacent epithelium in 137 
both replicates.  138 
 139 
Statistical analysis: 140 
Survival was summarised in each DNMT expression subgroup using the methods of Kaplan and 141 
Meier. Univariate Cox models were used to quantify the association between cohort characteristics 142 
and the risk of disease specific survival and time to local vulval recurrence, specifically the impact of 143 
overexpression of DNMT markers. Multivariable Cox modelling was performed to adjust the 144 
estimates of risk associated DNMT expression for known confounders. Given the limited size of each 145 
cohort there was scope to adjust for just one confounder other than the DNMT descriptor in each 146 
multivariable model. The patient characteristics were explored within each sub-cohort by DNMT 147 
expression through comparison of proportions via a chi-squared test, and comparison medians using a 148 
Wilcoxon rank-sum test. P values <0.05 were deemed statistically significant. Analyses were 149 
performed in Stata V12.1 150 
 151 
Pyrosequencing: 152 
Genomic DNA (500 ng) was bisulfite converted using EZ DNA methylation kit (Zymo Research). 153 
Pyrosequencing primers used for each of the promoter regions are shown in Supplemental table 1 154 
The PCR was performed in a total volume of 50 µl using 25 µl HotStart Taq master mix (Thermo 155 
Scientific) with 10pmol of primers and 10 µl of bisulfite-modified DNA. The pyrosequencing 156 
reactions were performed on a Pyromark ID system (Qiagen) and analysed using Pyro Q-CpG 157 
software (Qiagen). 158 
 159 
 160 
 161 
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Results 162 
Expression of DNMT1, DNMT3A and DNMT3B in VSCC 163 
DNMT1, DNMT3A and DNMT3B expression in the invasive component was compared to that in the 164 
normal adjacent epithelium. Replicate cases which were not reproducible were removed from our 165 
analysis. Therefore DNMT1, DNMT3A and DNMT3B expression in relation to prognosis was 166 
analysed in 66, 55 and 45 VSCC cases respectively. DNMT1 was over-expressed in 83% (55/66) of 167 
tumours, DNMT3A was over-expressed in 44% (24/55) and DNMT3B was over-expressed in 42% 168 
(18/45) of tumours contributing to this analysis. For every case with DNMT over-expression, all 169 
tumour cells stained positive in the invasive component. Representative examples of VSCC showing 170 
over-expression of DNMT3A, DNMT3B and DNMT1 compared to the normal adjacent epithelium 171 
(NAE) is shown in Figure 1. 172 
 173 
Risk of local vulval recurrence is associated with DNMT3A over-expression  174 
We set out to determine whether DNMT1, DNMT3A or DNMT3B over-expression is associated with 175 
the risk of LVR.   176 
DNMT3A: 13 of the 55 women in the DNMT3A cohort had a LVR. LVR free survival at 1, 3 177 
and 5 years was found to be 75.4%, 56.3% and 47.5%, respectively, when DNMT3A was over-178 
expressed, and 96.4%, 92.6% and 83.3% when it was not (Figure 2A). In a univariable analysis, 179 
DNMT3A over-expression was found to be associated with a 4.5 fold increased risk of LVR 180 
(HR=4.51, p= 0.012). Risk of LVR was also increased in patients with groin node metastasis 181 
(HR=4.72, p=0.005) (Table 1). In a multivariable analysis, DNMT3A over-expression continued to be 182 
associated with increased risk of developing a LVR after adjustment for disease stage (HR=6.00, 183 
p=0.003), groin node metastasis (HR=4.81, p=0.008), and the presence of LS adjacent to the primary 184 
tumour (HR=4.08, p=0.019).  185 
 186 
DNMT3B: 9 of the 45 women in the DNMT3B cohort had a LVR. LVR free survival at 1, 3 and 5 187 
years was found to be 88.5%, 63.0% and 56.8%, respectively, when DNMT3B was over-expressed, 188 
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and 100%, 94.1% and 77.4% when it was not (Figure 2A). Like DNMT3A, univariable analysis 189 
indicated that DNMT3B over-expression was associated with a significantly increased risk of LVR 190 
(HR=5.69, p=0.03) (Table 1). Risk of LVR was also increased in women with groin node metastasis 191 
(HR=4.07, p=0.04) and in those with tumours arising in a background of LS (HR=11.25, p=0.023) 192 
(Table 1). In a multivariable analysis, DNMT3B over-expression continued to be associated with 193 
increased risk of developing a LVR after adjustment for disease stage (HR=4.80, p=0.029). Unlike 194 
DNMT3A, the excess risk associated with DNMT3B over-expression was attenuated and ceased to be 195 
significant after adjustment for groin node metastasis (HR=4.18, p=0.088) and the  presence of LS 196 
adjacent to the primary tumour (HR=2.99, p=0.19)  197 
 198 
DNMT1: 14 of the 66 women in the DNMT1 cohort had a LVR. LVR free survival at 1, 3 and 5 years 199 
was found to be 91.2%, 81.3% and 75.0%, respectively, when DNMT1 was over-expressed and 200 
90.0%, 90.0% and 64.3% when it was not (Figure 2A). Unlike DNMT3A and DNMT3B, univariable 201 
analyses resulted in no evidence that DNMT1 over-expression increases risk of LVR (HR=0.77, 202 
p=0.691) (Table 1).  Risk of LVR was substantially increased in women with groin node metastasis 203 
(HR=4.84, p=0.006) and in those with tumours arising in a background of LS (HR=4.41, p=0.012) 204 
(Table 1). The risk of LVR associated with DNMT1 over-expression remained insignificant after 205 
adjustment.  206 
 207 
DNMT3A, DNMT3B or DNMT1 expression does not influence disease specific mortality 208 
We next set out to determine whether DNMT1, DNMT3A or DNMT3B expression influences disease 209 
mortality. However we found no significant difference in disease specific survival at 1, 3 and 5 years 210 
for each of the DNMT (Figure 2B). In both univariable and multivariable analysis DNMT1, 211 
DNMT3A and DNMT3B over-expression was not associated with increased mortality (Table 2). 212 
 213 
Over-expression of DNMT3A is associated with CDKN2A expression  214 
43 tumours from the VSCC cohort were tested for CDKN2A expression, which is indicative of HPV 215 
induced dysplasia [22]. Of the 39 tumours for which CDKN2A result was available, 15 (38.5%) 216 
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showed positive block staining which is characteristic of a transforming HPV infection and 24 were 217 
negative for  CDKN2A expression (Figure 3A and B). When we compared CDKN2A and DNMT 218 
expression, we found that in the 24 tumours negative for CDKN2A that over-expression of DNMT3A 219 
was significantly more common (33.3% vs. 0%, difference in proportions 33.3%, 95% CI 2.34-56.25). 220 
Representative examples showing CDKN2A expression in the absence of DNMT3A and vice versa 221 
are shown in Figure 3. The expression of DNMT1 and DNMT3B did not vary significantly with 222 
CDKN2A expression. We next examined the methylation status of the CDKN2A promoter using 223 
pyrosequencing and found that CDKN2A negative tumours were significantly more methylated than 224 
those tumours which were CDKN2A positive  (T-test 0.0014) (Figure 4).  Although the observations 225 
in our results point to a relationship between DNMT3A over-expression and the absence of CDKN2A 226 
expression, and a relationship between the absence of CDKN2A expression and hypermethylation of 227 
the CDKN2A promoter, we were not able to directly link the over-expression of DNMT3A to 228 
hypermethylation of the CDKN2A promoter. Although we show an association between DNMT3A 229 
over expression and CDKN2A expression (indicative of HPV induced dysplasia), there was no 230 
association between DNMT3A over-expression and HPV status when this was assigned using PCR 231 
based assays. 232 
 233 
Discussion 234 
Approximately one in four women with VSCC will have a LVR within five years after primary 235 
surgery [13]. Known risk factors for LVR are the clearance margin of the tumour, the depth of 236 
invasion by tumour cells and, as we reported recently, the presence of LS adjacent to the tumour [24, 237 
13]. However, more sophisticated predictors such as biomarkers capable of distinguishing cases likely 238 
to recur, are of clinical importance. 239 
Maintenance of DNA methylation by the DNMT is critical during development and in transcriptional 240 
regulation; however aberrant expression of the DNMT has been reported for a number of human 241 
cancers, including those of epithelial origin [16, 17, 19]. To date, expression of the DNMT in VSCC 242 
has not been examined, therefore, we evaluated the expression of these enzymes and correlated our 243 
10 
 
results with CDKN2A staining, clinicopathologic parameters and survival data to determine the 244 
prognostic significance of DNMT expression in vulvar cancer. 245 
 246 
Our data showed that DNMT3A over-expression but not DNMT1 or DNMT3B was associated with a 247 
significantly increased risk of LVR. This increased risk persisted after adjustment for groin node 248 
metastasis suggesting that over-expression is an important predictor of VSCC recurrence. It has also 249 
been shown for gastric carcinoma that DNMT3A over-expression while not DNMT3B or DNMT1 is 250 
associated with poor disease survival [25]. For both epithelial tumours over-expression of DNMT3A 251 
significantly contributes to disease recurrence or progression which may be associated with the 252 
disruption of similar molecular pathways, such as epithelial-to-mesenchymal transition (EMT). 253 
During EMT cells undergo a developmental switch from a polarized, epithelial phenotype to a highly 254 
motile fibroblastoid or mesenchymal phenotype, a central process during cancer progression [26]. It is 255 
recognised that VSCC with prominent fibromyxoid stroma have a poorer outcome. This stromal 256 
response is phenotypic of epithelial mesenchymal transition [27]. Vulval cancers like other epithelial 257 
malignancies, express a set of proteins which characterize strongly the transition from normal 258 
epithelium to invasive VSCC [28]. The importance of DNMT3A in the regulation of these proteins 259 
during EMT has recently been highlighted by Tan et al, where they show that a non-histone chromatin 260 
protein, HMGA2 remodels chromatin to favour binding of DNMT3A to the CDH1 promoter, thus 261 
achieving sustained silencing of E-cadherin expression and promoting tumour cell invasion [29]. 262 
Our results also showed that DNMT3A overexpression was inversely related to the expression of 263 
CDKN2A in these carcinomas.  Expression of CDKN2A is related to the regulation of Rb by the viral 264 
oncogene, E7. Following HPV integration into the host genome, E7 expression increases as does 265 
CDKN2A expression due to its accumulation in the cell [30]. These results may tie in with a recent 266 
finding published by Rodriguez et al, which suggests that HPV positive vulvar tumours may not 267 
progress through EMT while HPV negative tumours do, again suggesting a role for DNMT3A in the 268 
EMT process [28]. The presence of HPV when detected using PCR based methods did not reveal an 269 
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association with DNMT3A over expression, however this may not be surprising given that it may 270 
only be transcriptionally active HPV that is related to disease progression [22].  271 
Our results showed that over expression of DNMT3A and DNMT3B was associated with an LVR but 272 
not survival. Identifying factors which are associated with local recurrence but not survival is not 273 
unusual; in fact, these results are consistent with findings in our cohort study which shows that 274 
mortality/survival is not influenced by LVR [13]. We also found in this study that women who 275 
developed LVR also went on to develop at least one further episode of LVR within 2.3 years [13]. 276 
These findings might also suggest that DNMT3A is over expressed in a subset of less aggressive 277 
tumours, a type associated with recurrence but not death. However given this is the first time we have 278 
established this association, further work on the molecular biology of these VSCC tumours would be 279 
necessary to fully understand this. 280 
In summary, we have demonstrated that molecular profiling of the tumour and its adjacent epithelium 281 
may be used to predict treatment outcomes in patients with VSCC. We have shown, for the first time 282 
that DNMT3A over-expression is associated with tumours that do not contain transcriptionally active 283 
HPV and have an increased risk of LVR. Our study suggests that DNMT3A may be used as a 284 
surrogate marker for HPV-negative tumours and serve as a biomarker to identify those patients who 285 
are at risk of developing LVR. Furthermore, given that a family of propiophenone derivatives have 286 
recently been shown to be specific DNMT3A inhibitors in cancer cells, raises the interesting 287 
possibility of testing these novel agents for their use in the prevention of some vulvar recurrences 288 
[31]. This of course requires further evaluation including clinical studies. 289 
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 389 
 390 
Figure and Table Legends 391 
Figure 1: Examples of VSCC with over-expression of DNMT1, DNMT3A or DNMT3B. The H score 392 
of the invasive areas of the tumour was compared with that of the non-neoplastic squamous 393 
epithelium lying adjacent to the invasive lesion (NAE).  394 
 395 
Figure 2A: Univariate analysis showing a statistically significant increased risk of local vulval 396 
recurrence when there is over-expression of DNMT3A and DNMT3B but not DNMT1. 2B: 397 
Univariate analysis showing a statistically insignificant risk of disease specific survival (i.e. VSCC 398 
related death) when there is over-expression of DNMT3A, DNMT3B and DNMT1. 399 
 400 
16 
 
Figure 3: Low level DNMT3A expression in tumours with CDKN2A overexpression. A 401 
representative example of a tumour in which both the immature keratinising and keratinising 402 
components of the tumour show strong CDKN2A expression but low level DNMT3A expression. 403 
 404 
Figure 4: Graph showing the average methylation of the P16 promoter in 43 VSCC tumours. 405 
 406 
 407 
Table 1: Univariable analysis showing the risk of Local Vulval Recurrence in relation to DNMT 408 
expression and patient and disease related prognostic factors.  409 
 410 
Table 2: Univariable analysis showing the risk of death from VSCC in relation to DNMT over-411 
expression and patient and disease related prognostic factors. 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
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 429 
 430 
Covariate 
DNMT 1 (N=66)   DNMT3A (N=55)   DNMT3B (N=45) 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) P-value 
DNMT over-
expression 
Not over-
expressed 
1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
Over-
expressed 
0.77 (0.21, 2.77) 0.691 4.51 (1.40, 14.49) 0.012 5.69 (1.17, 27.57) 0.031 
Age 
≤70 1 (reference)  1 (reference)  1 (reference)  
>70 1.16 (0.40, 3.36) 0.781 0.73 (0.25, 2.11) 0.563 0.55 (0.14, 2.21) 0.400 
Smoking status 
Smoker/Ex-
Smoker 
1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
No 7.42 (0.96, 57.32) 0.055 3.76 (0.83, 17.06) 0.086 3.28 (0.40, 26.81) 0.269 
Not 
mentioned 
1.88 (0.12, 30.10) 0.657 0.57 (0.05, 6.25) 0.642 1.06 (0.07, 16.99) 0.968 
Stage if disease 
1/2 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
3/4 2.8 (0.95, 8.25) 0.062 3.34 (1.14, 9.77) 0.028 1.69 (0.15, 33.35) 0.437 
Tumour size 
≤4cm 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
> 4cm 1.16 (0.39, 3.46) 0.789 1.07 (0.36, 3.18) 0.909 0.98 (0.45, 6.35) 0.990 
Multifocal 
disease 
No 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
Yes 1.37 (0.43, 4.39) 0.593 1.71 (0.54, 5.47) 0.363 1.04 (0.22, 5.04) 0.96 
Groin node 
involvement 
No 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
Yes 4.84 (1.56, 15.07) 0.006 4.72 (1.60, 13.93) 0.005 4.07 (1.06, 15.59) 0.04 
Lymphovascular 
space 
involvement 
No 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
Unavailable 1.78 (0.48, 6.60) 0.388 2.20 (0.55, 8.79) 0.266 0.00 (0.00, .) 1 
Yes 0.37 (0.08, 1.73) 0.209 1.20 (0.37, 3.95) 0.76 0.63 (0.16, 2.53) 0.514 
Excision margin 
status 
Optimum 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
Incomplete 0.00 (0.00, .) 1 0.00 (0.00, .) 1 0.00 (0.00, .) 1 
Sub-optimum 0.85 (0.26, 2.76) 0.786 0.72 (0.22, 2.33) 0.58 0.82 (0.20, 3.30) 0.781 
Unavailable 4.05 (0.49, 33.68) 0.196 3.45 (0.41, 28.78) 0.253 1.00 ( ., .) . 
Tumour 
differentiation 
Well 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
Moderate 1.56 (0.41, 5.83) 0.512 1.24 (0.33, 4.61) 0.751 1.09 (0.22, 5.44) 0.917 
Poorly 0.93 (0.22, 3.91) 0.924 0.87 (0.23, 3.26) 0.84 0.49 (0.08, 2.96) 0.438 
Not graded 1.93 (0.37, 9.98) 0.431 0.00 (0.00, .) 1 0.76 (0.08, 7.40) 0.816 
LS+/-VIN 
No LS 1 (reference) 
 
1 (reference) 
 
1 (reference) 
 
LS, +/- Vin 4.41 (1.38, 14.07) 0.012 2.47 (0.83, 7.36) 0.106 11.25 (1.40, 90.14) 0.023 
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Covariate 
DNMT1 (N=66) DNMT3A  (N=55) DNMT3B  (N=45) 
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
DNMT  over-
expression 
No 1 (reference)   1 (reference)   1 (reference)   
Yes 0.85 (0.28, 2.56) 0.772 2.02 (0.66, 6.21) 0.219 1.48 (0.45, 4.86) 0.517 
Age 
≤70  1 (reference)   1 (reference)   1 (reference)   
>70 1.34 (0.53, 3.42) 0.535 2.35(0.71, 7.77) 0.162 0.82 (0.25, 2.69) 0.740 
Smoking status 
Smoker/Ex-Smoker 1 (reference)   1 (reference)   1 (reference)   
Never smoker 1.24 (0.39, 3.94) 0.721 1.08 (0.27, 4.33) 0.917 0.57 (0.13, 2.57) 0.466 
Not mentioned 2.26 (0.60, 8.57) 0.23 1.91 (0.42, 8.77) 0.403 1.25 (0.28, 5.63) 0.775 
Stage of disease 
1/2 1 (reference)   1 (reference)   1 (reference)   
3/4 9.95 (3.26, 30.43) 0.000 6.27 (1.71, 22.98) 0.006 6.94 (1.49, 32.3) 0.014 
Tumour size 
≤4cm 1 (reference)   1 (reference)   1 (reference)   
>4cm 3.63 (1.28, 10.26) 0.015 4.86 (1.25, 18.87) 0.022 1.92 (0.54, 6.83) 0.312 
Multifocal 
disease 
No 1 (reference)   1 (reference)   1 (reference)   
Yes 0.69 (0.20, 2.37) 0.551 0.80 (0.18, 3.61) 0.77 0.89 (0.19, 4.15) 0.884 
Groin node 
involvement 
No  1 (reference)   1 (reference)   1 (reference)   
Yes 9.68 (3.51, 26.66) <0.01 6.16 (1.87, 20.31) 0.003 6.50 (1.66, 25.5) 0.007 
Lymphovascular 
space 
involvement 
No 1 (reference)   1 (reference)   1 (reference)   
Yes 1.30 (0.48, 3.49) 0.607 2.07 (0.58, 7.33) 0.261 1.79 (0.52, 6.17) 0.356 
Unavailable 1.66 (0.45, 6.17) 0.446 2.61 (0.57, 11.87) 0.214 0.00 (0.00, .) 1 
Excision margin 
status 
Optimum  1 (reference)   1 (reference)   1 (reference)   
Incomplete 3.92 (1.00, 15.29) 0.049 7.82 (0.83, 73.32) 0.072 3.76 (0.41, 34.8) 0.243 
Sub-optimum 1.84 (0.60, 5.64) 0.289 2.79 (0.77, 10.07) 0.118 1.52 (0.38, 6.13) 0.554 
Unavailable 7.96 (1.98, 31.95) 0.003 10.73 (1.82, 63.33) 0.009 1.3e+18 ( ., .) . 
Tumour 
differentiation 
Well  1 (reference)   1 (reference)   1 (reference)   
Moderate 1.89 (0.53, 6.72) 0.326 1.27 (0.34, 4.80) 0.724 1.29 (0.29, 5.85) 0.738 
Poorly 2.90 (0.95, 8.89) 0.062 0.85 (0.21, 3.45) 0.818 1.13 (0.25, 5.07) 0.87 
Not graded 0.00 (0.00, .) 1 0.00 (0.00, .) 1 0.00 (0.00, .) 1 
LS+/-VIN No LS  1 (reference)   1 (reference)   1 (reference)   
  LS, +/- Vin 1.41 (0.57, 3.47) 0.458 0.92 (0.30, 2.82) 0.887 3.22 (0.85, 12.1) 0.084 
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